Lenvatinib
Treatment for Liver Cancer Due To Nash
Typical Dosage: 8mg or 12mg orally once daily
Effectiveness
85%
Safety Score
40%
Clinical Trials
5
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
8mg or 12mg orally once daily
Time to Effect
1-2 months
Treatment Duration
until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$240,000
Monitoring:$8,000
Side Effect Mgmt:$10,000
Total Annual:$258,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$1,075,000
Cost per Remission
$12,900,000
Comparison vs Sorafenib
Cost Difference
+$200,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Lenvatinib Outcomes
for Liver Cancer Due To Nash
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+24%
Remission Rate
+2%
Common Side Effects
Hypertension (grade 3-4)
+24%
Fatigue
+44%
Diarrhea
+39%
Decreased appetite
+34%
Proteinuria
+26%
Palmar-plantar erythrodysesthesia
+26%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov